|
|
|
|
|
|
|
|
ILPROGRESS IN OVARIAN CANCER TREATMENT THROUGH GCIG COLLABORATIVE TRIALSCANCER RESEARCH AND CLINICAL ONCOLOGY FOR THE NEXT DECADE
Abstract
"Ovarian cancer is a relatively uncommon
tumour and progress in treatment has occured through small increments
requiring large-scale
trials. The Gynecological Cancer InterGroup was
formed in 1994 to encourage collaboration and avoid unnecessary
repetition
of research. Trials conducted by the
International Collaborative for Ovarian Neoplasia (ICON) Group and the
EORTC, Canadian
and Australian groups were the catalysts to
bring together a more formal collaboration of established national
trials groups.
The aims of the GCIG are to promote
international cooperation in clinical research, perform studies in rare
tumours, stimulate
evidence-based medicine and support educational
activities. Over the years, the GCIG has conducted many different
trials,
including GOG182-ICON5, the largest and fastest
recruiting trial in ovarian cancer, held four international consensus
conferences
on ovarian cancer to review evidence and set
standards, and developed strategies for research. A section of the GCIG
is directed
towards the facilitation of academic research
through harmonization of methodologies and developing common approaches
to lessen
the bureaucracy of clinical trial regulations.
The success of the GCIG results from
its relationship between participants, based on mutual respect, equality
and recognition
of the intellectual contribution from individual
group members. Landmark trials that have pushed forward our knowledge
will
be presented; however, the recognition that
ovarian cancer is not a single disease but one with an heterogenous
biology underlines
the need for a concerted international approach
to trials in what are effectively rare tumours. Maintenance of
intellectual
independence from industry is a major challenge
as the costs rise through ever increasing complex trial regulations.
However,
the current 23 Groups from Europe, North and
Central America, Far East and Australia represent a powerful body to
influence
industry and help direct future research."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.